Anti-PD-1/PD-L1

DRUG3 trials

Sponsors

Shanghai Zhongshan Hospital, Centre Leon Berard

Conditions

Advanced Solid TumorsHepatocellular CarcinomaMetastatic Solid Tumors

Phase 2

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Active, not recruitingNCT05605496

Centre Leon BerardAdvanced Solid Tumors, Metastatic Solid Tumors

Start: 2023-01-06End: 2026-11-24Updated: 2026-02-10

Unknown Phase

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

Shanghai Zhongshan HospitalHepatocellular Carcinoma

Start: 2021-06-15End: 2024-12-31Target: 15Updated: 2022-03-31

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

Shanghai Zhongshan HospitalHepatocellular Carcinoma

Start: 2023-01-26End: 2025-12-31Target: 20Updated: 2023-02-02

Related Papers

IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies.

Journal of Clinical Oncology2025-05-28